Zobrazeno 1 - 10
of 124
pro vyhledávání: '"RYO TOYOZAWA"'
Autor:
Hirotsugu Kenmotsu, MD, PhD, Kazuko Sakai, PhD, Keita Mori, PhD, Terufumi Kato, MD, Shunichi Sugawara, MD, PhD, Keisuke Kirita, MD, PhD, Yasuto Yoneshima, MD, PhD, Koichi Azuma, MD, PhD, Kazumi Nishino, MD, PhD, Shunsuke Teraoka, MD, Ryo Koyama, MD, PhD, Ken Masuda, MD, PhD, Hidetoshi Hayashi, MD, PhD, Ryo Toyozawa, MD, PhD, Satoru Miura, MD, PhD, Yuki Sato, MD, PhD, Kazuhiko Nakagawa, MD, PhD, Nobuyuki Yamamoto, MD, PhD, Kazuto Nishio, MD, PhD, Toshiaki Takahashi, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 11, Pp 100716- (2024)
Introduction: EGFR tyrosine kinase inhibitors have been the standard treatment for patients with NSCLC who have sensitive EGFR mutations. This study revealed final analysis survival data, biomarkers, and resistance mechanisms of osimertinib plus beva
Externí odkaz:
https://doaj.org/article/4c7148e01a2e473a80756678fc890a30
Autor:
Koichi Goto, Yoshimasa Shiraishi, Haruyasu Murakami, Hidehito Horinouchi, Ryo Toyozawa, Masayuki Takeda, Makiko Uno, Nigel Crawford, Joseph McGill, Takeshi Jimbo, Masato Ishigami, Gensuke Takayama, Shintaro Nakayama, Shoichi Ohwada, Makoto Nishio
Publikováno v:
Cancer Medicine, Vol 12, Iss 6, Pp 7090-7104 (2023)
Abstract Background Tyrosine kinase inhibitors (TKIs) are effective for the treatment of non‐small cell lung cancer (NSCLC) patients with activating mutations of the epidermal growth factor receptor (EGFR), but responses are not durable as tumors d
Externí odkaz:
https://doaj.org/article/4ccb84ac3b1f40d88e709e0bae4a3f6b
Autor:
Motoko Tachihara, MD, PhD, Akito Hata, MD, Takaaki Tokito, MD, PhD, Satoshi Hara, MD, PhD, Hideaki Okada, MD, Satoru Miura, MD, PhD, Yuki Sato, MD, Eriko Tabata, MD, PhD, Hiroshi Watanabe, MD, PhD, Yusuke Takayama, MD, PhD, Ryo Toyozawa, MD, PhD, Keiichi Ota, MD, PhD, Kazushige Wakuda, MD, PhD, Atsushi Nakamura, MD, PhD, Mototsugu Shimokawa, PhD, Nobuyuki Yamamoto, MD, PhD, Kazuhiko Nakagawa, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 10, Pp 100569- (2023)
Introduction: Docetaxel plus ramucirumab could be a promising treatment for chemo-naive elderly patients with NSCLC, but high incidence of febrile neutropenia (FN) is a critical concern. We thus adopted a routine primary prophylactic pegylated-granul
Externí odkaz:
https://doaj.org/article/8ba5db23f12745978f3d1100137cfd60
Autor:
Taichi Matsubara, Shinkichi Takamori, Takatoshi Fujishita, Ryo Toyozawa, Kensaku Ito, Masafumi Yamaguchi, Takashi Seto, Tatsuro Okamoto
Publikováno v:
Thoracic Cancer, Vol 12, Iss 23, Pp 3286-3289 (2021)
Abstract Concurrent chemoradiation therapy (CRT) is the standard of care for patients with unresectable stage II/III lung cancer. However, systemic chemotherapy is required for patients who are ineligible for radical radiation therapy. There is littl
Externí odkaz:
https://doaj.org/article/34e9b456402f4b74b9a51df3acabdd4c
Autor:
Shinkichi Takamori, Takashi Seto, Masafumi Yamaguchi, Fumihiko Kinoshita, Takatoshi Fujishita, Kensaku Ito, Ryo Toyozawa, Fumihiro Shoji, Tatsuro Okamoto
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Osimertinib is a standard therapy for the treatment of advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor gene (EGFR) mutations, but most patients with EGFR-mutant NSCLC develop secondary resistance to osimertinib.
Externí odkaz:
https://doaj.org/article/4ecec11b76544361abd4634eccc10400
Autor:
Shinkichi Takamori, Nobuki Furubayashi, Kenichi Taguchi, Taichi Matsubara, Takatoshi Fujishita, Kensaku Ito, Masafumi Yamaguchi, Ryo Toyozawa, Takashi Seto, Takahito Negishi, Motonobu Nakamura, Tatsuro Okamoto
Publikováno v:
Thoracic Cancer, Vol 12, Iss 14, Pp 2122-2125 (2021)
Abstract Immune checkpoint inhibitors (ICIs) have become the standard of care for the treatment of non‐small cell lung cancer (NSCLC). With the increasing use of ICIs, clinicians should be familiar with their immune‐related adverse events, includ
Externí odkaz:
https://doaj.org/article/2a2caac2e4584c3fb28387f6506f550b
Autor:
Ryo Toyozawa, Fumihiro Shoji, Takanori Yamashita, Fumihiko Kinoshita, Shinkichi Takamori, Takatoshi Fujishita, Kensaku Ito, Koji Yamazaki, Naoki Nakashima, Tatsuro Okamoto
Publikováno v:
BMJ Open, Vol 12, Iss 6 (2022)
Externí odkaz:
https://doaj.org/article/da225ab746d64addbe74b8a682a23a0d
Autor:
Mototsugu Shimokawa, Hiroshi Tanaka, Nobuyuki Yamamoto, Koichi Azuma, Hidetoshi Hayashi, Ryo Toyozawa, Kazumi Nishino, Kazuhiko Nakagawa, Isamu Okamoto, Hideo Saka, Takashi Seto, Kaname Nosaki, Shunichi Sugawara, Haruyasu Murakami, Terufumi Kato, Seiji Niho, Masahide Oki, Hiroshige Yoshioka, Haruko Daga, Rie Tohnai
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 2 (2022)
Background PD-L1 expression on tumor cells is a marker of PD-1/PD-L1 antibody treatment efficacy for advanced non-small cell lung cancer (NSCLC). PD-L1 antibody (atezolizumab) prolongs overall survival (OS) compared with platinum doublet as first-lin
Externí odkaz:
https://doaj.org/article/937f7175a0d347ba8b5600013b992f6c
Autor:
Shinkichi Takamori, Taichi Matsubara, Takatoshi Fujishita, Kensaku Ito, Ryo Toyozawa, Takashi Seto, Masafumi Yamaguchi, Tatsuro Okamoto
Publikováno v:
Thoracic Cancer, Vol 12, Iss 6, Pp 978-980 (2021)
Abstract Mesenchymal‐epithelial transition (MET) pathway activation is associated with the mechanisms that influence properties affecting cancer cell survival and invasiveness. The MET exon 14 skipping mutation (METex14del) is found in 2%–3% of p
Externí odkaz:
https://doaj.org/article/36b2fd8fb9cc4e20b01117b12a42c531
Autor:
Shinkichi Takamori, Taichi Matsubara, Naoki Haratake, Gouji Toyokawa, Takatoshi Fujishita, Ryo Toyozawa, Kensaku Ito, Masafumi Yamaguchi, Kenichi Taguchi, Tatsuro Okamoto, Takashi Seto
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Molecular drugs targeting mutated or rearranged oncogene drivers have become one of the standard recognized treatments in patients with advanced and recurrent non-small cell lung cancer. RET is located in the long arm of human chromosome 10 and encod
Externí odkaz:
https://doaj.org/article/aea39422f5a440a787d6dd5fd222dbc6